REMARKS

The Examiner states in the Restriction Requirement that the application contains claims directed to the following patentably distinct species: a neurodegenerative disease, a selective alpha-2B adrenergic receptor agonist, and a selective alpha 2B/2C adrenergic receptor agonist. The Examiner states that all of the claims (claims 1-15) are generic, but requires that the Applicants elect a single disclosed species in the event that no generic claims are finally held to be allowable.

As the Examiner finds all the claims to be generic, the Applicants do not in this paper amend or withdraw claims. In the event that the generic claims are not ultimately found to be allowable the Applicants elect Alzheimer's Disease as the neurodegenerative disease and AGN 197075 as the alpha-2B receptor agonist.

The undersigned authorizes the Director to charge any fees required or necessary for the filing, processing or entering of this paper or any of the papers transmitted with it, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/Joel B. German/

Date: February 26, 2007

Joel B. German, Esq.
Attorney of Record
Registration No. 48,676

Please direct all correspondence and inquires to:

Joel B. German, Esq.
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, CA 92612
Tel: (714) 246- 4920
Fax: (714) 246-4249